Abstract:Objective: Currently there is no cure for cystic fibrosis (CF) disease and lung is the most affected organ [1Cooney A Gene. 2018 Nov; 9: 538Crossref Scopus (72) Google Scholar]. Gene replacement is a promising strategy to treat this disease. However, the two big challenges that have impeded its success are the absence of: (1) an efficient and safe gene delivery reagent to transfect the target cells, and (2) a stable plasmid that enables high and sustained CF transmembrane conductance regulator (CFTR) expression. Thus, the aim of this work is to develop a non-viral CFTR gene replacement system for lung CF disease to overcome these two challenges. Methods: A cationic highly branched poly(β-amino ester) (HPAE) polymer [2Zhou D Sci Adv. 2016 Jun; 6e160010Google Scholar] with high transfection efficiency was used as a non-viral gene delivery reagent complexed to a CpG-depleted CFTR plasmid with high and sustained CFTR expression and expected lower immune response to transfect CF lung epithelial cells in vitro. Results: By using the HPAE for CFTR gene delivery, similar gene expression and higher cell viability (~98%) than commercial transfection reagents such as Xfect™ (~77%) and Lipofectamine™ 3000 (~51%) were achieved after 48 hours. Moreover, around 2400% and 120% higher CFTR protein levels compared to healthy human lung epithelial cells were obtained after 48 hours and 7 days of transfection in CF lung epithelial cells, respectively. Conclusion: We developed a very promising HPAE/CFTR polyplex system as it is demonstrated that only 6–10% CFTR protein expression of healthy lung epithelial cells is enough to restore the ionic transport in CF lung epithelial cells [3Johnson L Nat Genet. 1992 Sep; 2: 21-25Crossref PubMed Scopus (382) Google Scholar]. In addition, a nebulization system for testing this HPAE/CFTR polyplex system in vivo by inhalation in mice is being currently developed. The expected results could potentially support the future use of this technology as a gene therapy for treating lung cystic fibrosis disease.

CRISPR/Cas9 gene editing therapies for cystic fibrosis

Application of CRISPR gene editing technology in cystic fibrosis treatment

CRISPR-Cas9 Mediated Gene Correction of CFTR Mutations in Cystic Fibrosis: Evaluating Efficacy, Safety, and Long-Term Outcomes in Patient-Derived Lung Organoids

Development and application of CRISPR/Cas9 technologies in genomic editing.

Gene Editing and Genetic Lung Disease. Basic Research Meets Therapeutic Application

Systemic in utero gene editing as a treatment for cystic fibrosis

Gene therapy for cystic fibrosis: Challenges and prospects

WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

How can gene editing of human pluripotent stem cells help understand the effect of genetics on respiratory diseases?

Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders

Investigating Adverse Genomic and Regulatory Changes Caused by Replacement of the Full-length CFTR cDNA Using Cas9 and AAV

CRISPR/Cas9 therapeutics: progress and prospects

A Cell-Based Optimised Approach for Rapid and Efficient Gene Editing of Human Pluripotent Stem Cells

Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

Genetic medicines for CF: Hype versus reality

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells

Current landscape of cystic fibrosis gene therapy

Functional rescue of F508del-CFTR through revertant mutations introduced by CRISPR base editing

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

A Prospective Treatment Option for Lysosomal Storage Diseases: CRISPR/Cas9 Gene Editing Technology for Mutation Correction in Induced Pluripotent Stem Cells